This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

DUSA's CEO Discusses Q2 2012 Results - Earnings Call Transcript

DUSA Pharmaceuticals Inc. (DUSA)

Q2 2012 Results Earnings Call

August 2, 2012 8:30 AM ET

Executives

Bob Doman – President and CEO

Rich Christopher – Vice President, Finance and CFO

Analysts

Henry Scott – Roth Capital

Nick Halen – Sidoti & Company

Seamus Fernandez – Leerink Swann

Ken Trbovich – C.K. Cooper

Presentation

Operator

Good day, ladies and gentlemen. And welcome to the DUSA Pharmaceuticals Second Quarter 2012 Corporate Highlights and Financial Results Teleconference. At this time, all participants are in a listen-only mode and later, we will conduct a question-and-answer session, and instructions will be given at that time. (Operator Instructions)

As a reminder, this conference is being recorded. I would now like to introduce your host for today’s conference, Bob Doman. Sir, you may begin.

Bob Doman

Good morning, everyone. Thank you for joining us today for our second quarter 2012 corporate highlights and financial results conference call. After some opening comments I’ll turn the call over to Rich Christopher who will cover our financial results.

Please be reminded, while the primary purpose of the call is to review results, be advised that our comments and answers to your questions may contain certain forward-looking statements.

The forward-looking statements are subject to a number of risks and uncertainties associated with the company’s business. Additional information which may affect our business prospects is available in the company’s SEC filings.

We are pleased to report today that DUSA posted a very positive second quarter of the year. Sales results were strong, gross margin dollars were up significantly and we generated $2.3 million in positive cash flow.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,671.29 -58.82 -0.33%
S&P 500 2,070.26 -6.52 -0.31%
NASDAQ 4,996.0390 -13.1750 -0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs